ESPE Yearbook of Paediatric Endocrinology

ESPE Yearbook of Paediatric Endocrinology

ISSN 1662-4009 (online)

Published by BioScientifica
Previous issue | Volume 21 | ESPEYB21

Yearbook of Paediatric Endocrinology 2024

5. Bone, Growth Plate and Mineral Metabolism

Novel Treatments

Previous section
Advances in Clinical Practice
Table of contents
Next section
Advances in Growth, Bone Biology and Mineral Metabolism

ey0021.5-7 | Novel Treatments

5.7. Burosumab vs conventional therapy in children with x-linked hypophosphatemia: results of the open-label, phase 3 extension period

ey0021.5-8 | Novel Treatments

5.8. Management of RANKL-mediated disorders with denosumab in children and adolescents: a global expert guidance document

ey0021.5-9 | Novel Treatments

5.9. Safety and efficacy of denosumab in children with osteogenesis imperfecta-the first prospective comparative study

ey0021.5-10 | Novel Treatments

5.10. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

ey0021.5-11 | Novel Treatments

5.11. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial

ey0021.5-12 | Novel Treatments

5.12. Once-weekly transCon CNP (navepegritide) in children with achondroplasia (ACcomplisH): a phase 2, multicentre, randomised, double-Blind, placebo-controlled, dose-escalation trial

ey0021.5-13 | Novel Treatments

5.13. Low-dose infigratinib increases bone growth and corrects growth plate abnormalities in an achondroplasia mouse model

Published by BioScientifica

ESPE Yearbook of Paediatric Endocrinology
ISSN 1662-4009 (Online)
© Bioscientifica 2025 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more